Monday, February 01, 2021 10:14:11 AM
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
>>> Trip Advisor IS A GROWING STOCK PICK BOARD NOW <<< *** I take PLUS1 donations *** PREeBCGQKPrikA4C1DmrAizAHFDoiiUZA2
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM